Innate Pharma (IPH) Q2 2024 earnings summary

Executive summary

• Focused on advancing a differentiated pipeline of antibody-based therapeutics in oncology and immunology, leveraging innate immunity and antibody engineering, with proprietary and partnered assets including lacutamab, ANKET NK cell engagers, and ADCs.

• Key programs include lacutamab (CTCL, mycosis fungoides, Sézary syndrome), ANKET® platform (multiple assets in Phase 1/2), and ADCs targeting Nectin-4, with significant clinical and regulatory milestones anticipated.

• Partnerships with AstraZeneca and Sanofi continue to progress, supporting both late- and early-stage development.

• Cash position of €102.1m as of June 30, 2024, expected to fund operations through end of 2025.

• Net loss of €24.8m for H1 2024, compared to net income of €1.7m in H1 2023, driven by lower collaboration and licensing revenue.

Financial highlights

• Revenue and other income for H1 2024 totaled €12.3m, mainly from collaboration/licensing and government funding, down from €40.2m in H1 2023.

• Operating expenses were €38.7m, with 75% allocated to R&D; R&D expenses decreased by €2.4m to €29.1m, mainly due to lower personnel and other costs.

• G&A expenses increased slightly to €9.6m, mainly from higher consulting and property costs.

• Net financial income was €1.5m, down from €2.1m, mainly due to unfavorable FX movements.

• Net cash generated from operating activities was €3.0m, a significant improvement from €11.5m used in H1 2023.

Outlook and guidance

• Cash runway expected to last through end of 2025.

• Multiple clinical data readouts and R&D catalysts expected over the next two years, including FDA interaction for lacutamab, Phase 2 data in PTCL, and Monalizumab Phase 3 readout.

• Expects to incur further losses until significant revenues from drug candidates are realized; future operations depend on R&D success, regulatory approvals, and additional financing.

• Investor meeting scheduled for October 3rd in New York to discuss pipeline and growth strategy.